Comparing the effects of intralesional Meglumine Antimonate injection alone and intralesional Meglumine Antimonate injection plus local barberry root extract in cutaneous leishmaniosis treatment

A comparative study of the effects of intralesional Meglumine Antimonate injection alone and intralesional Meglumine Antimonate injection plus local barberry root extract on improvement of skin lesions of patients with cutaneous leishmaniasis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017060117756N16

Enrollment

Registered

2017-06-02

Start date

2013-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention Group: The cases received weekly intralesional Meglumine Antimonate injection plus 10% barberry root extract cream three times a day for 8 consecutive weeks. Intervention

Treatment - Drugs

Intervention Group: The cases received weekly intralesional Meglumine Antimonate injection plus 10% barberry root extract cream three times a day for 8 consecutive weeks.

Control Group: The controls received weekly intralesional Meglumine Antimonate injection plus placebo for 8 consecutive weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Positive direct smear in terms of Leishman-Donovan body; time passed less than 6 months from legion onset; no other treatment received for leishmaniasis during the last three months; informed consent for participation; lesion located is in upper limbs or the face. Exclusion criteria: Allergy to Meglumine (severe local reactions or anaphylaxis) or topical compounds used; irregular visits; incidence of secondary infection of the lesions based on clinical features and the therapist’s judgment ; presence of systemic treatment indications for cutaneous leishmaniosis including lesions on joints, number of lesions more than or equal to 5, lesion size more than or equal to 5 cm.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Enduration. Timepoint: On the last injection and 6 weeks later. Method of measurement: ruler.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Razmara Farzaghi

Mashhad University of Medical Sciences

RazmaraM941@mums.ac.ir00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026